10 research outputs found
Structural and mechanistic analysis of ATPase inhibitors targeting mycobacterial DNA gyrase
Objectives To evaluate the efficacy of two novel compounds against mycobacteria and determine the molecular basis of their action on DNA gyrase using structural and mechanistic approaches. Methods Redx03863 and Redx04739 were tested in antibacterial assays, and also against their target, DNA gyrase, using DNA supercoiling and ATPase assays. X-ray crystallography was used to determine the structure of the gyrase B protein ATPase sub-domain from Mycobacterium smegmatis complexed with the aminocoumarin drug novobiocin, and structures of the same domain from Mycobacterium thermoresistibile complexed with novobiocin, and also with Redx03863. Results Both compounds, Redx03863 and Redx04739, were active against selected Gram-positive and Gram-negative species, with Redx03863 being the more potent, and Redx04739 showing selectivity against M. smegmatis. Both compounds were potent inhibitors of the supercoiling and ATPase reactions of DNA gyrase, but did not appreciably affect the ATP-independent relaxation reaction. The structure of Redx03863 bound to the gyrase B protein ATPase sub-domain from M. thermoresistibile shows that it binds at a site adjacent to the ATP- and novobiocin-binding sites. We found that most of the mutations that we made in the Redx03863-binding pocket, based on the structure, rendered gyrase inactive. Conclusions Redx03863 and Redx04739 inhibit gyrase by preventing the binding of ATP. The fact that the Redx03863-binding pocket is distinct from that of novobiocin, coupled with the lack of activity of resistant mutants, suggests that such compounds could have potential to be further exploited as antibiotics
Discovery and structure-activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors
There is an urgent and unmet medical need for new antibacterial drugs that tackle infections caused by multidrug-resistant (MDR) pathogens. During the course of our wider efforts to discover and exploit novel mechanism of action antibacterials, we have identified a novel series of isothiazolone based inhibitors of bacterial type II topoisomerase. Compounds from the class displayed excellent activity against both Gram-positive and Gram-negative bacteria with encouraging activity against a panel of MDR clinical Escherichia coli isolates when compared to ciprofloxacin. Representative compounds also displayed a promising in vitro safety profile
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase
According to the World Health Organization (WHO), approximately 1.7 million deaths per year are caused by tuberculosis infections. Furthermore, it has been predicted that, by 2050, antibacterial resistance will be the cause of approximately 10 million deaths annually if the issue is not tackled. As a result, novel approaches to treating broad-spectrum bacterial infections are of vital importance. During the course of our wider efforts to discover unique methods of targeting multidrug-resistant (MDR) pathogens, we identified a novel series of amide-linked pyrimido[4,5-b]indol-8-amine inhibitors of bacterial type II topoisomerases. Compounds from the series were highly potent against gram-positive bacteria and mycobacteria, with excellent potency being retained against a panel of relevant Mycobacterium tuberculosis drug-resistant clinical isolates
Novel enolate chemistry of diketopiperazines : towards the total synthesis of (-)-brevianamide B
EThOS - Electronic Theses Online ServiceGBUnited Kingdo
Stability of Pillared Clays:Â Effect of Compaction on the Physicochemical Properties of Al-Pillared Clays
Novel bacterial topoisomerase inhibitors with potent broad-spectrum activity against drug-resistant bacteria
The Novel Bacterial Topoisomerase Inhibitor class is an investigational type of antibacterial inhibitor of DNA gyrase and topoisomerase IV that do not have cross-resistance with the quinolones. Here, we report the evaluation of the in vitro properties of a new series of this type of small molecules. Exemplar compounds selectively and potently inhibited the catalytic activities of Escherichia coli DNA gyrase and topoisomerase IV but did not block the DNA breakage-reunion step. Compounds showed broad-spectrum inhibitory activity against a wide range of Gram-positive and Gram-negative pathogens, including biodefence microorganisms, and Mycobacterium tuberculosis. No cross-resistance with quinolone-resistant Staphylococcus aureus and E. coli isolates was observed. Measured MIC90 values were 4 and 8 ÎŒg/mL against a panel of contemporary multidrug-resistant isolates of Acinetobacter baumannii and E. coli. In addition, representative compounds exhibited greater antibacterial potency than the quinolones against obligate anaerobic species. Spontaneous mutation rates were low, with frequencies-of-resistance typically <10-8 against E. coli and A. baumannii at concentrations equivalent to four-fold the MIC. Compound-resistant E. coli mutants isolated following serial passage were characterised by whole-genome sequencing and carried a single Arg38Leu amino acid substitution in the GyrA subunit of DNA gyrase. Preliminary in vitro safety data indicate that the series shows a promising therapeutic index and potential for low hERG inhibition (IC50 >100 ÎŒM). In summary, the compounds' distinct mechanism-of-action relative to the fluoroquinolones, whole-cell potency, low potential for resistance development and favorable in vitro safety profile warrant their continued investigation as potential broad-spectrum antibacterial agents
Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen
WNT
signaling is frequently deregulated in malignancy, particularly
in colon cancer, and plays a key role in the generation and maintenance
of cancer stem cells. We report the discovery and optimization of
a 3,4,5-trisubstituted pyridine <b>9</b> using a high-throughput
cell-based reporter assay of WNT pathway activity. We demonstrate
a twisted conformation about the pyridineâpiperidine bond of <b>9</b> by small-molecule X-ray crystallography. Medicinal chemistry
optimization to maintain this twisted conformation, cognisant of physicochemical
properties likely to maintain good cell permeability, led to <b>74</b> (CCT251545), a potent small-molecule inhibitor of WNT signaling
with good oral pharmacokinetics. We demonstrate inhibition of WNT
pathway activity in a solid human tumor xenograft model with evidence
for tumor growth inhibition following oral dosing. This work provides
a successful example of hypothesis-driven medicinal chemistry optimization
from a singleton hit against a cell-based pathway assay without knowledge
of the biochemical target